Cancer Research and Treatment

Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?

Journal of Clinical Oncology.2024; 42(4): 373. CrossRef

Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, C

Cancer Treatment and Research Communications.2024; 38: 100788. CrossRef

The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study

Jeffry Beta Tenggara, Andhika Rachman, Joedo Prihartono, Lisnawati Rachmadi, Sonar Soni Panigoro, Didik Setyo Heriyanto, Noorwati Sutandyo, Intan Russianna Nasution, Familia Bella Rahadiati, Ricci Steven, Rachelle Betsy, Samuel Juanputra, Aru Wisaksono Su

Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?

Suhaib Khateeb, Ludimila Cavalcante, Noor Alnairat, Meghana Singh, Ibrahim Halil Sahin, Azhar Saeed, Anwaar Saeed

Current Treatment Options in Oncology.2024; 25(4): 496. CrossRef

The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review

J. Bos, T.S. Groen-van Schooten, C.P. Brugman, F.S. Jamaludin, H.W.M. van Laarhoven, S. Derks

Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy

Hyung-Don Kim, Jinho Shin, In Hye Song, Jaewon Hyung, Hyungeun Lee, Min-Hee Ryu, Young Soo Park

Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer

Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images

Abhishek Vahadane, Shreya Sharma, Devraj Mandal, Madan Dabbeeru, Josephine Jakthong, Miguel Garcia-Guzman, Shantanu Majumdar, Chung-Wein Lee

Computers in Biology and Medicine.2023; 152: 106337. CrossRef

CT-based delta radiomics in predicting the prognosis of stage IV gastric cancer to immune checkpoint inhibitors

Jiazheng Li, Zifan Chen, Yang Chen, Jie Zhao, Meng He, Xiaoting Li, Li Zhang, Bin Dong, Xiaotian Zhang, Lei Tang, Lin Shen

Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis

Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer

Joan Choo, Ley Fang Kua, Mu Yar Soe, Bernadette Reyna Asuncion, Benjamin Kye Jyn Tan, Chong Boon Teo, Ryan Yong Kiat Tay, Jimmy So, Asim Shabbir, Kim Guowei, Hon Lyn Tan, Gloria Chan, Haoran Ma, Gokula Krishnan Ramachandran, Jeffrey H. Y. Lum, Cheng Ean C

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment

Hyun Jung Kwon, Yujun Park, Soo Kyung Nam, Enoch Kang, Ka‐Kyung Kim, Inhae Jeong, Yoonjin Kwak, Jeesun Yoon, Tae‐Yong Kim, Keun‐Wook Lee, Do‐Youn Oh, Seock‐Ah Im, Seong‐Ho Kong, Do Joong Park, Hyuk‐Joon Lee, Hyung‐Ho Kim, Han‐Kwang Yang, Hye Seung Lee

High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Marie E. Robert, Josef Rüschoff, Bharat Jasani, Rondell P. Graham, Sunil S. Badve, Manuel Rodriguez-Justo, Liudmila L. Kodach, Amitabh Srivastava, Hanlin L. Wang, Laura H. Tang, Giancarlo Troncone, Federico Rojo, Benjamin J. Van Treeck, James Pratt, Iryna

Heterogeneous distribution pattern of CD3+ tumor-infiltrated lymphocytes (TILs) and high combined positive score (CPS) favored the prognosis of resected early stage small-cell lung cancer

Liang Zhu, Guoping Cheng, Meijuan Wu, Ming Chen, Ying Jin

The Role of Immunotherapy in Esophageal and Gastric Cancer

Hans Dedecker, Laure-Anne Teuwen, Timon Vandamme, Andreas Domen, Hans Prenen

Clinical Colorectal Cancer.2023; 22(2): 175. CrossRef

Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer

Luca Licata, Marco Mariani, Federico Rossari, Giulia Viale, Giulia Notini, Matteo Maria Naldini, Carlo Bosi, Marta Piras, Matteo Dugo, Giampaolo Bianchini

PD‐L1andHLA‐class I expression status and their therapeutic implication in oesophageal small‐cell carcinoma

Satoshi Yamashita, Hiroyuki Abe, Hiroharu Yamashita, Koichi Yagi, Yasuyuki Seto, Tetsuo Ushiku

Programmed death-ligand 1 expression and overall survival in Thai patients with gastric cancer

Taned Chitapanarux, Pawut Gumrai, Sarawut Kongkarnka, Komson Wannasai, Nirush Lertprasertsuke

Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis

Xiaqing Xu, Jiaxing Chen, Wenxing Li, Chenlu Feng, Qian Liu, Wenfang Gao, Meng He

Clinical and Experimental Medicine.2023; 23(7): 3189. CrossRef

Targeted Therapies and Developing Precision Medicine in Gastric Cancer

Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review

T. N. Sotnikova, N. V. Danilova, P. G. Malkov, T. V. Polushkina

Advances in Molecular Oncology.2023; 10(2): 70. CrossRef

Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives

Yasushi Sato, Koichi Okamoto, Yutaka Kawano, Akinari Kasai, Tomoyuki Kawaguchi, Tamotsu Sagawa, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama

Journal of Clinical Medicine.2023; 12(14): 4646. CrossRef

Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases

Drolaiz H. W. Liu, Heike I. Grabsch, Beat Gloor, Rupert Langer, Bastian Dislich

Journal of Cancer Research and Clinical Oncology.2023; 149(14): 13345. CrossRef

Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials

Next generation immuno-oncology biomarkers in gastrointestinal cancer: what does the future hold?

Hassan Abushukair, Obada Ababneh, Ayah Al-Bzour, Ibrahim Halil Sahin, Anwaar Saeed

Expert Review of Molecular Diagnostics.2023; 23(10): 863. CrossRef

Impact of programmed death‐ligand 1 (PD‐L1) positivity on clinical and molecular features of patients with metastatic gastric cancer

Minkyue Shin, Soomin Ahn, Jaeyun Jung, Sujin Hyung, Kyoung‐Mee Kim, Seung Tae Kim, Won Ki Kang, Jeeyun Lee

Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy

Cancer Treatment Reviews.2023; 120: 102629. CrossRef

The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer

Ji Eun Choi, Jae Seok Lee, Min-Sun Jin, Ilias P. Nikas, Kwangsoo Kim, Sunah Yang, Soo Young Park, Jiwon Koh, Sohyeon Yang, Seock-Ah Im, Han Suk Ryu

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial

Shirish Gadgeel, Fred R. Hirsch, Keith Kerr, Fabrice Barlesi, Keunchil Park, Achim Rittmeyer, Wei Zou, Namrata Bhatia, Hartmut Koeppen, Sarah M. Paul, David Shames, Jing Yi, Christina Matheny, Marcus Ballinger, Mark McCleland, David R. Gandara

Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy

Hae Young Kim, Won Chang, Yoon Jin Lee, Ji Hoon Park, Jungheum Cho, Hee Young Na, Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Young Hoon Kim, Kyoung Ho Lee

Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies

Seminars in Diagnostic Pathology.2022; 39(1): 48. CrossRef

Histopathology of Gastrointestinal Immune-related Adverse Events

American Journal of Surgical Pathology.2022; 46(1): e15. CrossRef

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma

D.V.T. Catenacci, H.C. Chung, L. Shen, M. Moehler, H.H. Yoon, M.K. Rosales, Y.-K. Kang

PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance

Jie Lian, Guanjun Zhang, Yun Zhang, Heng Liu, Jiaojiao Zhang, Pengfei Nan, Wei Tian

Digestive and Liver Disease.2022; 54(10): 1419. CrossRef

Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer

Enoch Kang, Sung Cheol Jung, Soo Kyung Nam, Yujun Park, Soo Hyun Seo, Kyoung Un Park, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee

Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches

Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim

Immunotherapy use in oesophagogastric cancers—a review of the literature

Annabel Smith, Amitesh Roy, Christos S. Karapetis, Vy Broadbridge, Timothy Price

British Journal of Cancer.2022; 127(1): 21. CrossRef

Interspatial Distribution of Tumor and Immune Cells in Correlation with PD-L1 in Molecular Subtypes of Gastric Cancers

Bastian Dislich, Kirsten D. Mertz, Beat Gloor, Rupert Langer

Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma

Man Jiang, Chuantao Zhang, Yabin Hu, Tianjun Li, Guangjie Yang, Guanqun Wang, Jingjuan Zhu, Changfeng Shao, Helei Hou, Na Zhou, Kewei Liu, Xiaochun Zhang

Abdominal Computed Tomography Enhanced Image Features under an Automatic Segmentation Algorithm in Identification of Gastric Cancer and Gastric Lymphoma

Lihua Zhou, Hao Hu, Lei Zhou, Yi Zhou, Ahmed Faeq Hussein

Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

D.V.T. Catenacci, Y.-K. Kang, H.H. Yoon, B.Y. Shim, S.T. Kim, D.-Y. Oh, A.I. Spira, S.V. Ulahannan, E.J. Avery, P.M. Boland, J. Chao, H.C. Chung, F. Gardner, S.J. Klempner, K.-W. Lee, S.C. Oh, J. Peguero, M.B. Sonbol, L. Shen, M. Moehler, J. Sun, D. Li, M

Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

Hongzhen Cai, Man Li, Ruiyi Deng, Mopei Wang, Yanyan Shi

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update

Kathryn DeCarli, Jonathan Strosberg, Khaldoun Almhanna

Immunotherapy for Gastroesophageal Tumors: Is there still Hope for Efficacy?

Current Cancer Drug Targets.2022; 22(8): 651. CrossRef

The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers

Corina-Elena Minciuna, Mihai Tanase, Teodora Ecaterina Manuc, Stefan Tudor, Vlad Herlea, Mihnea P. Dragomir, George A. Calin, Catalin Vasilescu

Computational and Structural Biotechnology Journal.2022; 20: 5065. CrossRef

Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer

Zhen Jiang, Chen Wei, Yaomin Luo, Yang Xiao, Li Wang, Wubin Guo, Xiaoxia Yuan

Journal of Clinical Laboratory Analysis.2022;[Epub] CrossRef

Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate

Ji Min Kim, Binnari Kim, Eunji Kim, Minsun Jang, Jun Hun Cho, Hye Seung Lee, Yoonjin Kwak, Lingkang Huang, Radha Krishnan, Sally Y. Bai, Mounia Mounawar, Kyoung-Mee Kim

Molecular Diagnosis & Therapy.2022; 26(6): 679. CrossRef

High interobserver and intraobserver reproducibility among pathologists assessing PD‐L1 CPS across multiple indications

Shanthy Nuti, Yiwei Zhang, Nabila Zerrouki, Charlotte Roach, Gudrun Bänfer, George L Kumar, Edward Manna, Rolf Diezko, Kristopher Kersch, Josef Rüschoff, Bharat Jasani

Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer

Lianxi Song, Liang Zeng, Huan Yan, Qinqin Xu, Qing Xia, Jian Lei, Xiaoyan Chen, Xiaoping Hu, Zhan Wang, Hong Liu, Nong Yang, Yongchang Zhang

Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer

Jan Hrudka, Radoslav Matěj, Andrej Nikov, Igor Tomyak, Hana Fišerová, Karolína Jelínková, Petr Waldauf

Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma

Satoshi Yamashita, Hiroyuki Abe, Akiko Kunita, Hiroharu Yamashita, Yasuyuki Seto, Tetsuo Ushiku

MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma

Daniel VT Catenacci, Minori Rosales, Hyun Cheol Chung, Harry H Yoon, Lin Shen, Markus Moehler, Yoon-Koo Kang

PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study

You Jeong Heo, Binnari Kim, Hyunjin Kim, Soi Kim, Min Sun Jang, Kyoung-Mee Kim

Pathology - Research and Practice.2021; 218: 153338. CrossRef

Targeting Oncoimmune Drivers of Cancer Metastasis

Chie Kudo-Saito, Yukinori Ozaki, Hiroshi Imazeki, Hideyuki Hayashi, Jun Masuda, Hiroki Ozawa, Yamato Ogiwara

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M. Sholl, Keith M. Kerr, Sacha Gnjatic, Ignacio I. Wistuba, David L. Rimm, Ming Sound Tsao, Fred R. Hirsch

Nature Reviews Clinical Oncology.2021; 18(6): 345. CrossRef

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition

Nishant Thakur, Kwang Yeol Paik, Gyoyeon Hwang, Yosep Chong

Prädiktive Diagnostik für Checkpoint-Inhibitoren

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects

Enrico Munari, Francesca R. Mariotti, Linda Quatrini, Pietro Bertoglio, Nicola Tumino, Paola Vacca, Albino Eccher, Francesco Ciompi, Matteo Brunelli, Guido Martignoni, Giuseppe Bogina, Lorenzo Moretta

International Journal of Molecular Sciences.2021; 22(10): 5123. CrossRef

PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy

PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays

Applied Immunohistochemistry & Molecular Morphology.2021; 29(6): 462. CrossRef

Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry

Yujun Park, An Na Seo, Jiwon Koh, Soo Kyoung Nam, Yoonjin Kwak, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee

Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis

Tong Xie, Zhening Zhang, Xiaotian Zhang, Changsong Qi, Lin Shen, Zhi Peng

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer

Hye Jung Hwang, Soo Kyung Nam, Hyunjin Park, Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Woo Ho Kim, Hye Seung Lee

Journal of Pathology and Translational Medicine.2020; 54(5): 378. CrossRef